Class IIa / IIb Device

Class IIa / IIb Device - Axcellant

Class IIa / IIb Device

  1. lut 28, 2025

What Does 'Class IIa / IIb Device’ Mean?

Class IIa and IIb devices are categories of medical devices under the European Union’s Medical Device Regulation (MDR). These classifications indicate moderate-risk devices that require stricter controls than Class I devices but are considered less risky than Class III devices.

Class IIa typically includes non-invasive devices intended for short-term use, such as hearing aids or dental crowns. Class IIb devices are generally more invasive or used for longer periods, like surgical lasers or ventilators. The specific classification determines the level of regulatory scrutiny and conformity assessment procedures required before market approval.

Why Is the 'Class IIa / IIb Device’ Important in Clinical Research?

Understanding the classification of Class IIa and IIb devices is crucial in clinical research for determining the appropriate regulatory pathways and study designs. These classifications impact the level of clinical evidence required, influencing the complexity, duration, and cost of clinical investigations necessary for market approval.

Researchers and sponsors must tailor their clinical trial protocols and risk management strategies according to the device classification. This knowledge ensures compliance with regulatory requirements, guides the selection of appropriate endpoints, and informs the overall clinical development strategy for medical devices in these categories.

Good Practices and Procedures

  1. Conduct a thorough risk assessment to determine the specific classification (IIa or IIb) and identify potential hazards associated with the device’s intended use.
  2. Implement a robust quality management system (QMS) that addresses the specific requirements for Class IIa/IIb devices, including enhanced documentation and traceability measures.
  3. Engage early with a Notified Body to discuss the conformity assessment route and prepare a comprehensive technical file that meets MDR requirements for the device class.
  4. Design clinical investigations with appropriate sample sizes and follow-up periods to generate sufficient clinical evidence for demonstrating safety and performance.
  5. Develop and maintain a post-market surveillance plan tailored to the device’s risk profile, including proactive data collection and analysis methods.

Related Terms

Resources

How ACT EU Is Forcing a Global Approach to Trial Timelines

Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…

Axcellant at ICNC Berlin: Following the Future of Nuclear Cardiology – and helping bring it to clinical reality

The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…

Axcellant Establishes Advisory Board to Strengthen Clinical and Strategic Leadership

Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…